US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by iECURE, Inc.

News headline image
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
From iECURE, Inc.
Via Business Wire
News headline image
iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From iECURE, Inc.
Via Business Wire
Tickers DTIL
News headline image
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
From iECURE, Inc.
Via Business Wire
News headline image
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
From iECURE, Inc.
Via Business Wire